The drug combination of irinotecan, mitomycin and cisplatin has activity in inoperable upper gastro-oesophageal cancers but also has a high toxicity profile, British researchers report.
Investigators from St. Bartholomew’s Hospital in London administered the combination therapy to 38 of 45 outpatients: 26 out of 31 patients with gastro-oesophageal cancer and 12 of 14 patients with pancreatic cancer, in a 28-day cycle.
There was an overall response rate of 42 percent among both the gastro-oesophageal and the pancreatic cancer patients. Median survival was 9.5 months among the gastro-oesophageal patients and eight months among the pancreatic cancer patients.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!